Immune Checkpoint Inhibitors and Optic Neuropathy: A Systematic Review

REFERENCES

• Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11):805–812.2. doi:10.1038/nrc3153.
   PubMed Web of Science ®Google Scholar
• Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci. 2011;32(5):308–316. doi:10.1016/j.tips.2011.02.014.
   PubMed Web of Science ®Google Scholar
• Buchbinder E, Stephen Hodi F. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377–3383. doi:10.1172/JCI80012.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009.
   PubMed Web of Science ®Google Scholar
• Syn NL, Teng MW, Mok TS, et al. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. 2017;18(12):731–741. doi:10.1016/S1470-2045(17)30607-1.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. doi:10.1038/s12276-018-0191-1.
   PubMed Web of Science ®Google Scholar
• Jenkins R, Barbie D, Flaherty K. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9–16. doi:10.1038/bjc.2017.434.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Cousin S, Italiano A. Molecular pathways: immune checkpoint antibodies and their toxicities. Clin Cancer Res. 2016;22(18):4550–4555. doi:10.1158/1078-0432.CCR-15-2569.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015: 13.
   Google Scholar
• Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi:10.1097/CCO.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Miller MR, Newman NJ, Biousse V, et al. Optic Neuropathy. In: walsh & hoyt’s clinical neuro-ophthalmology: the essentials. In:: Lippincott Williams & Wilkins. USA: Philadelphia; 2007:293–295.
   Google Scholar
• Behbehani R. Clinical approach to optic neuropathies. Clin Ophthalmol. Sep 2007;1(3):233–246.
   PubMedGoogle Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;(372):160. doi:10.1136/bmj.n160.
   Google Scholar
• Critical Appraisal Skills Program United Kingdom. CASP Checklist for Cohort Studies. CASP UK: https://casp-uk.net/casp-tools-checklists/ Accessed 27 September, 2022.
   Google Scholar
• Chaudot F, Seve P, Rousseau A, et al. Ocular inflammation induced by immune checkpoint inhibitors. J Clin Med. 2022;11(17):17. doi:10.3390/jcm11174993.
   Web of Science ®Google Scholar
• Kelly H, Johnson J, Jakubecz C, et al. Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic. J Neuroimmunol. 2022;370:577928. doi:10.1016/j.jneuroim.2022.577928.
   PubMed Web of Science ®Google Scholar
• Kim JM, Materin MA, Sznol M, et al. Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology. 2019;126(7):1058–1062. doi:10.1016/j.ophtha.2019.01.031.
   PubMed Web of Science ®Google Scholar
• Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol. 2021;41(4):519–530. doi:10.1097/WNO.0000000000001148.
   PubMed Web of Science ®Google Scholar
• Vogrig A, Muniz-Castillo S, Jubert B, et al. Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. e866-e875. 2021;96(6):e866–e875. doi:10.1212/WNL.0000000000011340.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Grauer DW, Henry DW, Rockey ML. Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. J Oncol Pharm Pract. 2019;25(3):544–550. doi:10.1177/1078155217744872.
   PubMed Web of Science ®Google Scholar
• Francis JH, Jaben K, Santomasso BD, et al. Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology. 2020;127(11):1585–1589. doi:10.1016/j.ophtha.2020.05.003.
   PubMed Web of Science ®Google Scholar
• Braun D, Getahun VY, Chiu AL, et al. Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment. Am J Ophthalmol. 2021;224:282–291. doi:10.1016/j.ajo.2020.12.013.
   PubMed Web of Science ®Google Scholar
• Kaur A, Doberstein T, Amberker RR, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience. Med. 2019;98.24.
   Web of Science ®Google Scholar
• L’Orphelin J, Varey E, Kammari A, et al. Severe late-onset grade iii-iv adverse events under immunotherapy: a retrospective study of 79 cases. Cancers (Basel). 2021;13:19.
   Web of Science ®Google Scholar
• Noble CW, Gangputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859.
   PubMed Web of Science ®Google Scholar
• Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol. 1972;87:135–139.
   PubMedGoogle Scholar
• Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009;127(12):1572–1580. doi:10.1001/archophthalmol.2009.311.
   PubMedGoogle Scholar
• Baker T, Johnson H, Kotapati S, et al. Cost-utility of nivolumab plus ipilimumab in first-line treatment of advanced melanoma in the United States: an analysis using long-term overall survival data from checkmate 067. Pharmacoecon Open. 2022;6(5):697–710. doi:10.1007/s41669-022-00348-0.
   PubMed Web of Science ®Google Scholar
• Squibb B-M.Phase 3 study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma. Clinicaltrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT01844505 Updated 23 June 2022. Accessed. 2022 October 6
   Google Scholar
• Khair DO, Bax HJ, Mele S, et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol. 2019:19 2022;10] (1017):453. doi:10.3389/fimmu.2019.00453.
   PubMedGoogle Scholar